Eli Lilly's exceptional financial results, surpassing expectations, are attributed to the outstanding sales of Zepbound and Mounjaro. These drugs, known for their efficacy and market acceptance, have propelled the company's revenue. CEO David Ricks emphasizes innovation and patient care, reflecting the company's strong R&D capabilities and future growth plans in new therapeutic areas.
#pharmaceutical #innovation #growth #healthcare #success

свернуть